Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01061775
Other study ID # 0903-028
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 2010
Est. completion date March 15, 2019

Study information

Verified date September 2019
Source Children's Hospitals and Clinics of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim of this study is to evaluate the effect of Exenatide on weight status (change in body mass index) of children treated for craniopharyngioma that have developed hypothalamic obesity at Children's Hospitals and Clinics of Minnesota. We hypothesize that Exenatide given to hypothalamic obese children for 6 months will reduce their body mass index significantly from baseline.


Description:

Hypothalamic obesity is when individuals suffer from acute weight gain after brain tumor treatment, involving secondary damage to the ventromedial nucleus of the hypothalamus, which may lead to obesity. The weight gain is uncontrolled and not receptive to diet and exercise interventions. The rate of long-term obesity in children diagnosed with craniopharyngioma can be as high as 50%. Exenatide, a drug indicated for diabetes, is an incretin mimicking agent that mimics the enhancement of glucose-dependent insulin secretion and several other antihyperglycemic actions of incretins has resulted in weight loss when given to diabetics. Exenatide shows potential to benefit patients suffering from hypothalamic obesity by slowing gastric emptying and therefore reducing food intake. Also increasing the glucagon-like peptide 1 (GLP-1) circulation, decreased due to obesity, at the already compromised GLP-1 receptor site of the hypothalamus could potentially help with regulation of appetite.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date March 15, 2019
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender All
Age group 10 Years to 21 Years
Eligibility Inclusion Criteria:

- >/=6 months post surgical or radiation or chemotherapy treatment for 1° craniopharyngiomas or other suprasellar tumors

- 10-21 years old

- Age-and sex-adjusted BMI >/=95%

- Parent sign consent and patient sign assent

Exclusion Criteria:

- < 6 months post surgical or radiation or chemotherapy treatment for 1° craniopharyngiomas or other suprasellar tumors

- Pregnant or breastfeeding, or those women who plan to get pregnant

- Renal impairment

- Gastroparesis

- Pancreatitis

- Diabetes

- <1 month post initiation of Metformin treatment

- Prescription or over-the-counter weight loss medications within 3 months of screening

- Are actively participating in, or have participated in a formal weight loss program within the last 3 months

- Have had bariatric surgery

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Exenatide
5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.

Locations

Country Name City State
United States Children's Hospital of Orange County Orange California
United States Children's Hospitals & Clincis of Minnesota Saint Paul Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Children's Hospitals and Clinics of Minnesota Amylin Pharmaceuticals, LLC.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary BMI Change BMI was collected at baseline and 24 weeks 24 weeks
Primary Waist to Height Ratio (WHtR) Waist circumference was measured at the natural waist level (midway between the lowest rib margin and the iliac crest) at baseline and 24 weeks 24 weeks
Secondary Childhood Eating Behavior Questionnaire (CEBQ) The Child Eating Behaviour Questionnaire (CEBQ) was designed as parent-report measure comprised of 35 items, each rated on a five-point likert scale that ranges from never to always. We utilized the CEBQ as a self-report measure during this study; it has not been validated for such use. For the purposes of this study, we looked at the Satiety Responsiveness Subscale Scores (5 questions; total scores could range from 5-25 with lower scores denoting a lower level of satiety). The results reported show the change between baseline and week 24 scores. 24 weeks
Secondary Calorie Intake Based on 3-day Diet Records Dietary data were collected via 3-day diet records (Crawford et al. 1994) twice during the study, at baseline and week 24. Three-day diet records were collected on consecutive days including one weekend day. A registered dietitian (RD) instructed subjects on dietary data collection at baseline appointment. Depending on the age and capacity of the subject, the patient, parent or a collaboration of both recorded dietary intake. A RD entered dietary data into Nutritionist Pro software (First DataBank, SanBruno, CA) and the mean difference was analyzed. 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT02849743 - Intranasal Oxytocin in Hypothalamic Obesity Phase 2
Recruiting NCT06217848 - The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study Early Phase 1
Withdrawn NCT05147415 - Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) Phase 2
Completed NCT00892073 - Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Phase 2
Not yet recruiting NCT06299891 - Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity Phase 2
Recruiting NCT06239116 - A Study of RM-718 in Healthy Subjects and in Patients With HO Phase 1
Completed NCT02664441 - Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Phase 3
Completed NCT04725240 - Open-Label Study of Setmelanotide in Hypothalamic Obesity Phase 2
Completed NCT03673813 - A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity
Not yet recruiting NCT06046443 - A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Phase 2
Withdrawn NCT03708913 - Neuromodulation for Hypothalamic Obesity N/A
Completed NCT02860923 - Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Phase 3
Completed NCT00171613 - A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients Phase 4
Recruiting NCT01783717 - Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage N/A
Enrolling by invitation NCT05774756 - A Trial of Setmelanotide in Acquired Hypothalamic Obesity Phase 3
Completed NCT05319301 - Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study) N/A

External Links